In sum, at present there is no consensus between the recent ICC2 and WHO1 classifications regarding the capacity of NPM1 mutations alone to define AML, leaving uncertainty whether cases of CMML with NPM1 mutation should be classified as AML. The gene discussed is NPM1; the disease is acute myeloid leukemia.